A61M11/02

Therapeutic agents for delivery using a catheter and pressure source
11696984 · 2023-07-11 · ·

The present embodiments provide systems and methods suitable for delivering a therapeutic agent to a target site. A container holds the therapeutic agent and a pressure source has pressurized fluid in selective fluid communication with at least a portion of the container. A catheter, in fluid communication with the container, has a lumen sized for delivery of the therapeutic agent to a target site. In one embodiment, a diameter of particles of the therapeutic agent is in a range of between about 1 micron to about 925 microns, a mass of the particles of the therapeutic agent is in a range of between about 0.0001 mg to about 0.5 mg, a ratio of an inner diameter of the catheter to the diameter of particles is at least 4:1, and a regulated pressure of the pressurized fluid is between about 0.01 psi to about 100 psi.

Therapeutic agents for delivery using a catheter and pressure source
11696984 · 2023-07-11 · ·

The present embodiments provide systems and methods suitable for delivering a therapeutic agent to a target site. A container holds the therapeutic agent and a pressure source has pressurized fluid in selective fluid communication with at least a portion of the container. A catheter, in fluid communication with the container, has a lumen sized for delivery of the therapeutic agent to a target site. In one embodiment, a diameter of particles of the therapeutic agent is in a range of between about 1 micron to about 925 microns, a mass of the particles of the therapeutic agent is in a range of between about 0.0001 mg to about 0.5 mg, a ratio of an inner diameter of the catheter to the diameter of particles is at least 4:1, and a regulated pressure of the pressurized fluid is between about 0.01 psi to about 100 psi.

Fluid or powdery product dispensing device
11690962 · 2023-07-04 · ·

A dispenser device for fluid or powder, including an air expeller (20) and a reservoir (30). The reservoir (30) has an air inlet (31) connected to the air expeller (20) and a composition outlet (32) connected to a dispenser opening (10), and is removably mounted on the air expeller. After actuation, the empty reservoir can be removed from the air expeller and replaced with a new reservoir. The air inlet (31) is closed by a first closure element (40) and the composition outlet (32) is closed by a second closure element (50). A mechanical opening system (61, 62) co-operates with the first and second closure elements to expel each closure element from the closed position. The mechanical opening system has a first rod (61) secured to the air expeller (20), and a second rod (62) secured to the dispenser head (1), co-operating with a closure element during actuation.

Devices, systems, and methods for dry powder therapies

Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

HANDS-FREE ELECTROLYTE DISPENSER
20230001108 · 2023-01-05 ·

A system is described for the hands-free administration of a nutritional supplement matrix to the oral mucosa. A two-piece mouthpiece is formed in a nozzle cap that accepts canisters with the nutritional supplement matrix under pressure. Bite pressure administered by a user to an upper moveable portion of the two-piece mouthpiece may activate the dispensing of an atomized mixture of the nutritional supplement matrix. A flexible joiner between the upper moveable portion and the lower fixed portion of the two-piece mouthpiece may compress, fold, or otherwise collapse under the bite pressure from the user.

HANDS-FREE ELECTROLYTE DISPENSER
20230001108 · 2023-01-05 ·

A system is described for the hands-free administration of a nutritional supplement matrix to the oral mucosa. A two-piece mouthpiece is formed in a nozzle cap that accepts canisters with the nutritional supplement matrix under pressure. Bite pressure administered by a user to an upper moveable portion of the two-piece mouthpiece may activate the dispensing of an atomized mixture of the nutritional supplement matrix. A flexible joiner between the upper moveable portion and the lower fixed portion of the two-piece mouthpiece may compress, fold, or otherwise collapse under the bite pressure from the user.

POWDER DISPERSION METHODS AND DEVICES

A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives, powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.

INHALATION DEVICE
20250229042 · 2025-07-17 ·

The present invention provides for the integration of drug dispersion methods into a drug or medicine delivery system. The drug dispersion methods used include shear (e.g., air across a drug, with or without a gas assist), capillary flow or a venturi effect, mechanical means such as spinning, vibration, or impaction, and turbulence (e.g., using mesh screens, or restrictions in the air path). These methods of drug dispersion allow for all of the drug in the system to be released, allowing control of the dosage size. These methods also provide for drug metering, fluidization, entrainment, deaggragation and deagglomeration. The present invention also provides for the integration of a drug sealing system into the device. The drug sealing system provides a way of blocking the migration of drug from one area of the package to another. The drug seal system can also provide a method of tightly containing the drug until the package is opened, of directing airflow through the package and of managing and containing the drug during the package/device manufacturing process.